Brief: Celyad Provides Update On Allogeneic CAR-T Franchise

Celyad Oncology SA

01/06/2020 06:06

June 1 (Reuters) - CELYAD SA  CYAD.BR :
    * CELYAD PROVIDES UPDATE ON ALLOGENEIC CAR-T FRANCHISE
INCLUDING
CYAD-101 AND SHRNA PLATFORM AT THE 2020 ASCO VIRTUAL SCIENTIFIC
PROGRAM
    * TWO PATIENTS ACHIEVED A CONFIRMED PARTIAL RESPONSE AND
NINE
PATIENTS ACHIEVED STABLE DISEASE, LEADING TO A DISEASE CONTROL
RATE OF 73%
    * OVERALL SAFETY AND CLINICAL ACTIVITY DATA ARE
HLA-INDEPENDENT
INDICATING THAT CYAD-101 CELLS CAN BE USED IN A BROAD PATIENT
POPULATION REGARDLESS OF HLA HAPLOTYPE
    * EXPANSION COHORT OF ALLOSHRINK TRIAL EVALUATING CYAD-101
FOLLOWING FOLFIRI PRECONDITIONING CHEMOTHERAPY IS EXPECTED TO
BEGIN IN Q4
    * EXPANSION COHORT OF ALLOSHRINK TRIAL EVALUATING CYAD-101
FOLLOWING FOLFIRI PRECONDITIONING CHEMOTHERAPY EXPECTED TO BEGIN
IN Q4 2020
    * SHRNA PLATFORM FOR NEXT-GENERATION ALLOGENEIC CAR-T
CANDIDATES
PROVIDES PROOF-OF-PRINCIPLE TO SIMULTANEOUSLY KNOCKDOWN UP TO
FOUR GENES IN SINGLE CONSTRUCT
    * CYAD-101, SHOWS ENCOURAGING CLINICAL ACTIVITY WITH NO
EVIDENCE
OF GRAFT-VERSUS-HOST DISEASE IN RELAPSED/REFRACTORY METASTATIC
COLORECTAL CANCER PATIENTS

Source text for Eikon:  ID:nBw6lTDhDa 
Further company coverage:  CYAD.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))